Cutler Group LP Alaunos Therapeutics, Inc. Transaction History

Cutler Group LP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 25, 2022	BUY	$1.04 - $322.5 $4,260 - $1.32 Million	4,097 New	4,097 $7,000
Q1 2022 Apr 14, 2022	SELL	$0.62 - $1.17 $868 - $1,638	-1,400 Closed	0 $0
Q4 2021 Jan 18, 2022	BUY	$1.09 - $1.89 $109 - $189	100 Added 7.69%	1,400 $1,000
Q3 2021 Oct 26, 2021	BUY	$1.44 - $2.73 $432 - $819	300 Added 30.0%	1,300 $2,000
Q2 2021 Jul 19, 2021	BUY	$2.63 - $3.67 $2,630 - $3,670	1,000 New	1,000 $2,000
Q1 2019 May 10, 2019	SELL	$2.0 - $4.4 $2,094 - $4,606	-1,047 Closed	0 $0
Q4 2018 Feb 05, 2019	SELL	$1.61 - $3.62 $16,175 - $36,370	-10,047 Reduced 90.56%	1,047 $1,000
Q3 2018 Nov 07, 2018	BUY	$2.26 - $3.27 $12,536 - $18,138	5,547 Added 100.0%	11,094 $33,000
Q2 2018 Aug 10, 2018	SELL	$3.02 - $4.94 $1,812 - $2,964	-600 Reduced 9.76%	5,547 $16,000
Q1 2018 May 11, 2018	BUY	$3.46 - $5.14 $5,190 - $7,709	1,500 Added 32.28%	6,147 $24,000
Q4 2017 Jan 17, 2018	SELL	$4.0 - $6.54 $7,200 - $11,772	-1,800 Reduced 27.92%	4,647 $19,000
Q3 2017 Oct 17, 2017	BUY	$4.99 - $6.57 $32,170 - $42,356	6,447	6,447 $39,000

92.6K

Ticker TCRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,182,000
Market Cap $607M
Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.